Neuroblastoma is a cancer of the sympathetic nervous system that accounts for approximately 10% of all pediatric oncology deaths 1 . Here, we report a genome-wide association study of 2,817 neuroblastoma cases and 7,473 controls. We identified two new associations at 6q16, the first within HACE1 (rs4336470; combined P = 2.7 × 10 −11 ; odds ratio 1.26, 95% confidence interval (CI) 1.18-1.35) and the second within LIN28B (rs17065417; combined P = 1.2 × 10 −8 ; odds ratio 1.38, 95% CI 1.23-1.54). Expression of LIN28B and let-7 miRNA correlated with rs17065417 genotype in neuroblastoma cell lines, and we observed significant growth inhibition upon depletion of LIN28B, specifically in neuroblastoma cells that were homozygous for the risk allele. Low HACE1 and high LIN28B expression in diagnostic primary neuroblastomas were associated with worse overall survival (P = 0.008 and 0.014, respectively). Taken together, these data show that common variants in HACE1 and LIN28B influence neuroblastoma susceptibility and indicate that both genes likely have a role in disease progression.
Neuroblastoma is a malignancy derived from the developing sympa thetic nervous system. The median age at diagnosis is 17 months, and the survival rate for the most aggressive subset remains approximately 50%, despite intensive multimodal cytotoxic therapy 1 and recent advances in immunotherapy 2 . The genetic etiology of familial neuro blastoma, which accounts for approximately 1% of cases, has recently come into focus [3] [4] [5] [6] ; however, the genetic and environmental factors that cause sporadic neuroblastoma remain largely unknown. We have recently reported common SNPs within or upstream of LINC00340 and LOC729177 (also known as FLJ44180), BARD1, LMO1, DUSP12, HSD17B12 and DDX4IL31RA and a common copynumber varia tion (CNV) within NBPF23 are each highly associated with neuro blastoma [7] [8] [9] [10] [11] . Collectively, however, these variants still account for only a small portion of neuroblastoma heritability, and it is likely that additional predisposition loci remain to be discovered.
To identify additional variants associated with neuroblastoma, we expanded our previous genomewide association study (GWAS) discovery cohort and analyzed 2,101 neuroblastoma cases accrued through the North America-based Children's Oncology Group (Supplementary Table 1 ) with 4,202 control subjects of European ancestry who were matched genetically and by genotyping array version to minimize genomic inflation (Online Methods and Supplementary Figs. 1 and 2). All subjects were genotyped using the Illumina HumanHap550 or Quad610 BeadChips. We restricted our analysis to the SNPs present on both platforms that passed our quality control metrics; the genomic control inflation factor was 1.14 ( Supplementary Fig. 3 ). Evaluation of the first three principal compo nents in cases and controls confirmed that the slightly high inflation factor was not due to gross population stratification ( Supplementary  Fig. 4 ). Clusters of SNPs from six genomic loci reached genome wide significance (P values ranged from 7.8 × 10 −16 to 4.8 × 10 −8 ; Supplementary Fig. 1 and Supplementary Table 2), including three SNPs within LINC00340 and LOC729177 (FLJ44180) at 6p22 (P values ranged from 7.8 × 10 −16 to 1.7 × 0 −14 ), ten SNPs within or near BARD1 at 2q35 (P values ranged from 4.1 × 10 −14 to 3.7 × 10 −8 ), two SNPs within LMO1 at 11p15 (P values ranged from 1.2 × 10 −13 to 3.8 × 10 −10 ) and one SNP within HSD17B12 at 11p11 (P = 4.8 × 10 −8 ), further confirming our previous reports [7] [8] [9] [10] . In addition, we identified one SNP (rs4696715) at chromosome 4p16 and two SNPs (rs4336470 and rs9404576) at 6q16 that have not been reported previously (P values ranged from 1.8 × 10 −8 to 3.4 × 10 −8 ; Table 1 ). Several genotyped SNPs in strong linkage disequilibrium (LD) with rs4696715 at 4p16 did not show evidence for association with neuroblastoma; therefore, this SNP was not considered further.
Closer examination of the 6q16 locus identified four additional SNPs that showed association (P < 1 × 10 −4 ) with neuroblastoma ( Table 1 and Supplementary Table 3 ). Three of these SNPs mapped to introns of the HACE1 gene (encoding HECT domain-and ankyrin repeat-containing E3 ubiquitin protein ligase 1) and exhibited a mod erate degree of LD with rs4336470. The fourth SNP (rs17065417; P = 1.8 × 10 −7 ) mapped to an intron of the LIN28B gene (encoding lin 28 homolog B) and showed very little evidence for LD with rs4336470 in multiple HapMap populations (Supplementary Fig. 5 ). To ensure that these results were not influenced by subtle substructure in the discovery phase, we included the first 20 principal components as covariates in a logistic regression analysis. This reduced the inflation factor to 1.04 but did not alter our conclusions regarding regions that were associated at genomewide significance, and the P values for SNPs at the newly identified 6q16 locus were essentially unchanged (Supplementary Table 4 ). Finally, we conditioned the analysis of the 6q16 SNPs on rs4336470 to investigate whether there might be more than one independent association signal at 6q16. As expected, the associations for SNPs in modest LD with rs4336470 were no longer statistically significant after conditioning, and these SNPs clearly represent one signal (Supplementary Table 5 ). In contrast, whereas the signal at rs17065417 was attenuated, it remained significant (P = 2.5 × 10 −4 ; Supplementary Table 5 Tables 6 and 7) , and we observed only weak evidence for epistasis at the other significant loci (Supplementary Tables 8 and 9 ), suggest ing that each may act independently to confer risk.
We next sought to replicate the rs4336470 and rs17065417 asso ciations in an Italian cohort of 351 cases and 780 controls using PCRbased genotyping. Both SNPs showed evidence for association in the same direction as seen in the discovery effort ( Table 1 and  Supplementary Table 3 ). To assess whether these variants influ ence susceptibility in other ancestry groups and to seek additional replication, we analyzed a third independent case series comprised of 365 AfricanAmerican neuroblastoma cases and 2,491 geneti cally matched controls, all genotyped on Illumina HumanHap550 or Quad610 BeadChips. After accounting for African admixture in logistic regression analysis, the genomic inflation factor was 1.02, as described previously 12 (Online Methods and Supplementary Fig. 6 ). Consistent with the lower incidence rate of neuroblastoma in African Americans 13 , the rs4336470[T] protective allele is actually the major allele in AfricanAmericans, whereas it is the minor allele in individ uals of European ancestry. Despite these observed differences in allele frequencies, all SNPs mapped to HACE1 replicated robustly in the AfricanAmerican cohort (P values ranged from 1.3 × 10 −4 to 1.4 × 10 −3 ; Table 1 and Supplementary Table 3) , and all associations were in the same direction. Allele frequencies for the LIN28B SNP rs17065417 were comparable across populations of different ances try and showed a trend toward association in AfricanAmericans in the same direction as in the EuropeanAmerican discovery and Italian replication cohorts ( l e t t e r s npg 1 1 2 8 VOLUME 44 | NUMBER 10 | OCTOBER 2012 Nature GeNetics l e t t e r s significance threshold (P values ranged from 2.7 × 10 −11 to 1.6 × 10 −7 ; Table 1 ).
To identify variants at the 6q16 locus that were not assayed directly on the Illumina SNP arrays, we performed genotype imputation in our discovery cohort using data from the 1000 Genomes Project. This analysis identified ten additional SNPs associated with genome wide significance (P values ranged from 4.4 × 10 −9 to 5.7 × 10 −8 ; Fig. 1 ). Five of these imputed SNPs were in strong LD with rs4336470 (r 2 > 0.8 in the 1000 Genomes Project European (EUR) population); three mapped to introns of HACE1 and the other two were located just downstream of HACE1 (Fig. 1a) . The remaining five imputed SNPs reaching genomewide significance were in strong LD with rs17065417 (r 2 > 0.8 in the 1000 Genomes Project EUR population) and were located within introns of LIN28B (Fig. 1b) . In total, we iden tified 46 imputed SNPs that showed strong evidence for association (P < 1.0 × 10 −6 ; Supplementary Table 10). To further evaluate whether two independent association signals exist at 6q16, we conditioned the regional association analysis on either rs4336470 or rs17065417, finding that neither could fully account for the observed associa tions (Supplementary Fig. 7) . The signal at 6q16 was only abolished across the entire region after conditioning on both rs4336470 and rs17065417 ( Supplementary Fig. 8 ). Although we cannot rule out the possibility that both SNPs may be tagging the same underlying risk variant, these data are consistent with the presence of two inde pendent association signals at 6q16, one implicating HACE1 and the other LIN28B.
The HACE1 gene encodes an E3 ubiquitin protein ligase that was first identified in a sporadic Wilms' tumor that harbored a t(6:15)(q21;q21) translocation 15 npg l e t t e r s HACE1 is silenced in the majority of Wilms' tumors via hypermeth ylation of two CpG islands upstream of the transcriptional start site 15 . Similar epigenetic silencing has been reported in advanced colorectal cancer 16 and gastric carcinoma 17 . Indeed, HACE1 is downregulated in multiple human tumors and maps to a region of common deletion or loss of heterozygosity (LOH), consistent with a tumor suppressor function. Hace1null mice form spontaneous tumors in a wide array of tissues and are susceptible to additional cancer triggers, both genetic and environmental 18 . Through its E3 ubiquitin ligase function, HACE1 has been shown to suppress cell growth and anchorage independence of human tumor cells, includ ing in the neuroblastoma cell line IMR32 (ref. 18) . Studies suggest that HACE1 inhibits cell cycle progression during stress via regu lation of cyclin D1 degradation 18 and that HACE1 also regulates retinoic acid receptor (RAR) activity 19 . In addition to multiple somatic alterations involving the HACE1 locus, a constitutional t(5;6)(q21;q21) translocation that disrupts HACE1 was recently identified, making it a putative Wilms' tumor susceptibility gene 20 .
The LIN28B gene encodes a developmentally regulated RNA binding protein and is a key repressor of the let7 family of microRNAs (miRNAs) 21 . Both LIN28A and LIN28B are oncogenes that promote cellular transformation when ectopically overexpressed [22] [23] [24] , and high levels of expression of LIN28A or LIN28B have been observed in several human cancers and correlate with low let7 levels 22, 24 . Posttranscriptional regulation of let7 by LIN28A is required for normal development and contributes to the pluripotent state by pre venting let7-mediated differentiation of embryonic stem cells 21, 25, 26 . Overexpressing LIN28A or LIN28B or inhibiting let7 with antisense RNA promotes reprogramming of human and mouse fibroblasts into pluripotent stem cells 26, 27 . In a panel of 60 pediatric cancer cell lines 28 , LIN28B was consistently expressed at high levels in neuroblastoma (Supplementary Fig. 9) . Recently, LIN28B and let7 were also identi fied as key regulators of glucose homeostatis 29 and hematopoiesis 30 . To date, GWAS have identified variants in LIN28B associated with human height 31 and the ages of onset of puberty 32 and menarche 33 .
In addition, a recent candidate gene study identified a putative asso ciation with epithelial ovarian cancer 34 .
To investigate the functional relevance of neuroblastomaassociated SNPs within HACE1 and LIN28B, we first analyzed a set of 12 neu roblastoma cell lines with matched genomewide SNP genotyping and mRNA expression data. No correlation between rs4336470 and HACE1 mRNA expression was observed (P = 0.30), but LIN28B expression was significantly higher in cell lines homozygous for the rs17065417[A] risk allele compared to heterozygous cell lines (P = 0.02; Fig. 2a ). No cell lines tested were homozygous for the rs17065417[C] protective allele. LIN28A was not expressed in neu roblastoma cell lines, consistent with recent reports that LIN28A and LIN28B may be mutually exclusive in terms of their expression in cancer cells 21 . In addition to a correlation between rs17065417 geno type and LIN28B expression, we observed a strong positive correlation with MYCN expression (P = 0.0003; Fig. 2b) . We next confirmed LIN28B protein levels by protein blot in four cell lines at the extremes of LIN28B mRNA expression (Fig. 2c) . Cell lines expressing high amounts of LIN28B showed lower let7 expression across the entire miRNA family (Fig. 2d) . Transient knockdown of LIN28B resulted in significant growth inhibition in neuroblastoma cells homozygous for the rs17065417 risk allele that had high LIN28B expression (Fig. 3a-d) but not in the heterozygous cell line SKNAS that had low LIN28B expression (Fig. 3e,f) . Taken together, these data are consistent with the hypothesis that LIN28B promotes neuroblastoma tumorigen esis, in part through repression of let7 family miRNAs, and that the risk alleles are associated with growth advantage through increased LIN28B expression; however, additional studies with larger sample sizes are needed to confirm this model.
To examine the relevance of HACE1 and LIN28B in tumor samples, we assayed expression of both genes by quantitative RTPCR in a representative set of 87 primary tumors obtained at time of diagno sis (Supplementary Table 1 ). HACE1 expression was significantly lower (P = 0.002; Fig. 4a) , and LIN28B expression was significantly higher (P = 0.032; Fig. 4b Data sets for g and h correspond to those in e and f, respectively. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. npg lowrisk tumors. Accordingly, low HACE1 expression was associated with worse overall survival (P = 0.008; Fig. 4c) , as was high LIN28B expression (P = 0.015; Fig. 4d ). Analysis of four independent mRNA expression array data sets comprising 517 neuroblastoma tumors provided robust replication of these observations (Fig. 4e-h and Supplementary Figs. 10-12 ). These data support the hypothesis that HACE1 may function as a tumor suppressor and LIN28B as an oncogene in advanced neuroblastomas.
In conclusion, we have identified common variants within HACE1 and LIN28B that are associated with neuroblastoma. As with other genes identified in our ongoing GWAS efforts 8, 9, 35 , it is likely that the germline susceptibility variants identified here have an impor tant role, not only in tumor initiation, but also in disease progres sion via cis effects on major cancerassociated genes. Further study of HACE1 and LIN28B in neuroblastoma is warranted and may lead to new insights into the genetic and epigenetic mechanisms underlying an aggressive clinical phenotype. 
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Sample selection. Cases were defined as subjects who were diagnosed with neuroblastoma or ganglioneuroblastoma and registered through COG. All specimens were obtained at time of diagnosis, and the majority were anno tated with clinical and genomic information that included age at diagnosis, site of origin, INSS disease stage 38 , International Neuroblastoma Pathology Classification (INPC) 39 , MYCN oncogene copy number 40 , DNA index (ploidy) 41 , registration in clinical trial(s), eventfree and overall survival and second malignancies.
Control subjects were recruited from the Philadelphia region through the CHOP Health Care Network, including four primarycare clinics and several group practices and outpatient practices that included wellchild visits. Eligibility criteria for control subjects were (i) selfreporting as Caucasian; (ii) availability of 1.5 µg of highquality DNA from peripheral blood mono nuclear cells; and (iii) no serious underlying medical disorder, including cancer. The Research Ethics Board of the Children's Hospital of Philadelphia (CHOP) approved the study, and written informed consent was obtained from all subjects by nursing and medical assistant staff under the direction of CHOP clinicians.
Genome-wide SNP genotyping. Genotyping for both discovery and replication phases was performed using the Illumina Infinium II HumanHap550 and Human Quad610 BeadChips according to methods detailed elsewhere 11, 42, 43 and sum marized here. DNA samples were surveyed for quality, both by optical density spectrophotometry and PicoGreen assay (Invitrogen). A total of 750 ng of DNA isolated from blood was used to genotype each sample according to the manu facturer's guidelines. On day 1, genomic DNA was amplified 1,000-1,500fold. On day 2, amplified DNA was fragmented to ~300-600 bp in size and was pre cipitated and resuspended. Fragments were then hybridized to the BeadChip arrays. Singlebase extension (SBE) used a single probe sequence of approxi mately 50 bp designed to hybridize immediately adjacent to the SNP query site. Following targeted hybridization to the array, locusspecific primers for the arrayed SNP (attached to the beads) were extended with a single hapten labeled dideoxynucleotide in the SBE reaction. The haptens were subsequently detected by a multilayer immunohistochemical sandwich assay. The Illumina BeadArray Reader scanned each BeadChip at two wavelengths and created an image file. As BeadChip images were collected, intensity values were determined for all instances of each bead type, and data files were created that summarized intensity values for each bead type. These files consisted of intensity data that were loaded directly into the Illumina GenomeStudio genotype analysis software. Once normalization was complete, the cluster ing algorithm was run to evaluate cluster positions for each locus and assign individual genotypes. Only samples yielding a genotype call rate of ≥95% were considered for inclusion in this study.
Quality control and association testing for the discovery cohort. Overlap of the HumanHap550 v1, HumanHap550 v3 and Quad610 arrays. The dis covery cohort consisted of individuals genotyped on the HumanHap550 v1, HumanHap550 v3 and the Human Quad610 arrays. Our analysis only consid ered markers shared by all three arrays. The HumanHap550 v1 array contains 555,175 markers, the HumanHap550 v3 array contains 561,288 markers and the Quad610 array contains 620,901 markers. Overall, 535,752 markers are shared by all three arrays and were analyzed in this study.
Low genotype call rate (<95%).
Call rate was calculated on the basis of the number of 'no call' genotypes, with default genotyping calling algorithm implemented in Illumina GenomeStudio software. We did not consider any sample with a call rate of <95% for inclusion in this study. The call rate per individual was assessed by PLINK software and was confirmed to exceed 95% for all individuals, with an average genotyping rate of 99.85% across included individuals.
Inferring population structure for individuals of European ancestry.
Multidimensional scaling (MDS), as implemented in PLINK software, was used to infer population structure in the neuroblastoma data set. Comparing selfidentified ancestry with MDSinferred ancestry confirmed the reliability of MDS in identifying genetically inferred individuals of European ancestry (Supplementary Fig. 2 ).
Detection and elimination of cryptic relatedness and duplicate genotypes. To detect cryptic relatedness and potential duplicate genotypes within our data, we applied a twostep procedure to calculate pairwise identitybydescent (IBD) estimates between all individual case and control subjects. First, we exam ined the initial MDS and retained only those individuals of inferred European ancestry with call rates greater than 95%. Second, we recalculated genome wide identitybystate (IBS) estimates and IBD estimates in the remaining individuals of European ancestry using PLINK software. This twostep pro cedure ensures that allele frequency differences between populations do not lead to biases in IBD estimation. We applied a stringent threshold for detecting cryptic relatedness: any pairs of subjects with IBD of >0.15 were flagged, and one individual was removed, so that only unrelated subject remained in the final association test. A total of 11 neuroblastoma cases were excluded.
Low call rate per marker (<99%).
Markers with call rates of less than 99% were excluded from analysis. Call rates were calculated by PLINK software. A total of 49,130 markers were excluded from association analysis in this step.
Minor allele frequency (individuals of European ancestry).
Markers with minor allele frequency (MAF) of less than 5% were excluded from our analysis. MAFs were calculated by PLINK software. A total of 50,159 markers were excluded from association analysis in this step.
Hardy-Weinberg equilibrium (individuals of European ancestry).
Markers with HardyWeinberg equilibrium P values of less than 0.001 were excluded from analysis. A total of 11,953 markers were excluded from association analysis in this step.
Matching controls. On the basis of genomewide IBS estimates for all pairwise comparisons between case and control subjects, we identified two matched controls for each case to correct for the potential effects of population structure, as described previously 9 .
Final counts of subjects and markers passing quality control. Applying the qual ity control measures mentioned, we were left with 2,101 cases, 4,202 matching controls and 426,697 SNPs for association analysis.
Quality control and replication in the African-American cohort. The qual ity control procedure for the AfricanAmerican replication cohort is largely similar to those performed on the discovery cohort and is described in detail elsewhere 12 . The replication cohort after quality control consisted of a total of 365 cases and 2,491 control subjects who were genotyped on the Illumina HumanHap550 or Human610Quad BeadChips. Significant SNPs from the discovery effort (P < 1 × 10 −4 ) at the 6q16 loci were tested for association with neuroblastoma by logistic regression, including admixture estimate as a covariate.
Replication in Italian cohort. Genotyping of the top SNPs at HACE1 (rs4336470) and LIN28B (rs17065417) was performed using TaqMan SNP genotyping assays (Life Technology) for 350 neuroblastoma cases and 780 controls. Twenty DNA samples were also genotyped by Sanger sequencing for a further validation.
Meta-analysis. Metaanalysis was performed using the inversevariance method within the METAL 14 software package, and a fixedeffects model was assumed. The Cochran Q test was used to assess evidence of betweenstudy heterogeneity of effect sizes.
Genotype imputation. Imputation was performed with IMPUTE2 (ref. 44) using the worldwide 1000 Genomes Project Phase 1 interim data as reference (June 2011 release). Rather than preselecting a reference population, we elected to follow the approach of Howie et al. 45 and use a multipopulation refer ence panel with IMPUTE2. Genotypes for markers located on chromosome 6 were extracted and mapped to the hg19 human reference genome using the LiftOver tool. Multipopulation haplotype data from the 1000 Genomes Project Phase 1 interim release (June 2011) were downloaded from the 1000 Genomes Project website (see URLs). IMPUTE2 was applied with default parameters and npg Ne = 20,000. Following imputation, SNPs with MAF of <1% and/or IMPUTE2-info quality score of <0.8 were removed. To correctly account for uncertainty in the data resulting from the imputation process, the remaining SNPs were tested for association with neuroblastoma using the frequentist association test under the additive model implemented in SNPTEST 46 .
Genome-wide mRNA expression profiling of neuroblastoma cell lines. Genomewide mRNA expression profiling in neuroblastoma cell lines was performed using the Illumina WG6 expression array according to the manu facturer's specifications. Data were normalized using the average normaliza tion method provided in Illumina GenomeStudio software. Twosided t tests were performed at the gene level to assess differential expression in cell lines. P < 0.05 was considered significant. miRNA expression profiling of neuroblastoma cell lines. RNA from samples was labeled with oligonucleotides from the Illumina MicroRNA Expression Profiling Assay (version 1) and then hybridized to a universal Sentrix Array Matrix according to the manufacturer's specifications. Average signal values were normalized (rank invariant) using Illumina GenomeStudio software.
LIN28B protein detection.
Neuroblastoma cell lines were grown in T75 flasks under standard cell culture conditions. Wholecell lysates were extracted with 100 µl of cell extraction buffer (Invitrogen) containing protease inhibitors (Sigma) and phenylmethyl sulfonyl fluoride, were briefly sonicated and were rotated for 1 h at 4 °C. After 30 min of centrifugation at 4 °C, the supernatant was removed, and protein quantification was performed using the Bradford method. Lysates (100 µg) were separated on 4-12% BisTris gradient gels and were transferred to PVDF membranes. Membranes were washed and incu bated with antibodies directed against LIN28B (Cell Signaling Technology, 4196) and actin (Santa Cruz Biotechnology, sc1616).
LIN28B knockdown and monitoring of cell growth. For routine mainte nance, cells were grown in RPMI 1640 complete medium (Gibco, 22400) containing 10% FBS (Hyclone, SH 3007303), 1× antibiotic antimycotic (Gibco, 15240062) and 2 mM lglutamine (Gibco, 25030). On day 0, cells were seeded in triplicate into antibioticfree medium in 96well RTCES plates (ACEA). On day 1, using Dharmafect (Dharmacon, T200102), cells were transiently transfected with 50 nM of either a nontargeting negative control siRNA (Dharmacon, D008101005) or an siRNA directed against LIN28B (L028584010005). Realtime cell growth was monitored every 30 min for at least 96 h using the RTCES system, as previously described 3, 47 . Data presented are representative of at least three independent experiments. To monitor effi ciency of LIN28B knockdown, transfection was performed as described, and, 48 h later, RNA was isolated using the Qiagen mini extraction kit. Total RNA (200 ng) was primed with oligo(dT) and reverse transcribed using Superscript II reverse transcriptase (Invitrogen). Quantitative RTPCR using TaqMan gene expression assays (ABI) was performed. To monitor LIN28B protein knock down, protein was isolated 72 h after transfection. Protein blotting analysis was performed using antibodies directed against LIN28B and actin.
RT-PCR in primary neuroblastomas. TaqMan Gene expression assays for HACE1 (Hs00410879_m1) and LIN28B (Hs01013729_m1) were purchased through Applied Biosystems. Reactions were set up in duplicate, using 10 ng of cDNA in a 10µl reaction that contained 200 nM of probe, 900 nM of each amplification primer and 1× Realtime PCR Master Mix (Applied Biosystems). Standard curves were generated using serial dilutions of the neuroblastoma cell line Kelly. Samples were amplified on an Applied Biosystems 7900HT Sequence Detection System using standard cycling conditions, and data were collected and analyzed with SDS 2.3 software.
Survival analysis. Survival analyses were performed using the methods of Kaplan and Meier 48 . For overall survival, time was defined as the time from diagnosis until the time of death from disease or until the time of last contact if death did not occur. Individuals who were alive were censored at the time they were last known to be alive. Logrank P values < 0.05 were considered significant.
